Physicochemical Properties
| CAS # | 2928616-74-2 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Methuosis[1] |
| ln Vitro | JH530 (compound 5c) at 1 μM or 2 μM for 24 hours significantly alters the morphology of HCC1806 cells, which are characterized by intracellular vacuole formation, while having minimal impact on 184B5 cell viability and morphology [1]. Macrovesicular cell death is induced by JH530 (0.5, 1.0, 1.5 μM; 24 h) [1]. TNBC cell growth is successfully inhibited in vitro by JH530 (1 μM; 24 h)[1]. Rab7 and Lamp1 expression is upregulated in HCC1806 and MDA-MB-468 cells by JH530 (1.5 μM; 24 h) [1]. |
| ln Vivo | JH530 (compound 5c) was administered intraperitoneally once every two days for two weeks at a dose of 2.5 mg/kg or 5.0 mg/kg. At 2.5 mg/kg, the drug considerably suppressed the HCC1806 tumor weight; at 5 mg/kg, the tumor inhibitory effect was more evident[1]. |
| Cell Assay |
Cell Proliferation Assay[1] Cell Types: HCC1806, HCC1937, MDA-MB-468 cells Tested Concentrations: 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Expressed remarkable anti-proliferative activities invitro, with the IC50s were 0.70 μM, 0.92 μM, and 1.03 μM for three TNBC cells HCC1806, MDA-MB-468, and HCC1937, respectively. Cell Viability Assay[1] Cell Types: HCC1806, 184B5 Tested Concentrations: 1 μM or 2 μM Incubation Duration: 24 hrs (hours) Experimental Results: demonstrated notable cellular morphological changes at 1 μM, characterized by the accumulation of intracellular vacuoles in HCC1806 cells. Scarcely affected the morphology of 184B5 cells and cell viability. Western Blot Analysis[1] Cell Types: HCC1806; MDA-MB-468 Tested Concentrations: 0, 0.5, 1.0, 1.5 μM Incubation Duration: 24 hrs (hours) Experimental Results: Dose-dependently induces the increase of Rab7 and Lamp1 expression, and causes cell death by methuosis. Immunofluorescence[1] Cell Types: HCC1806, HCC1937, MDA-MB-468 cells Tested Concentrations: 1.5 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced the increase of |
| Animal Protocol |
Animal/Disease Models: HCC1806 cell xenograft mouse model[1] Doses: 2.5 mg/kg, 5.0 mg/kg Route of Administration: intraperitoneal (ip) injection (ip); once every 2 days Experimental Results: Inhibits HCC1806 tumor weight at 2.5 mg/kg Dramatically, while exhibit more apparent tumor suppressive effects at 5 mg/kg[1]. |
| References |
[1]. Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2023 Jun 8;66(11):7421-7437. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |